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CLINICAL SCIENCE
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Background: Prompt entry into HIV care is often hindered by
personal and structural barriers. Our objective was to evaluate the
impact of self-perceived barriers to health care on 1-year mortality
among newly diagnosed HIV-infected individuals in Durban,
South Africa.
Methods: Before HIV testing at 4 outpatient sites, adults ($18
years) were surveyed regarding perceived barriers to care
including (1) service delivery, (2) ﬁnancial, (3) personal health
perception, (4) logistical, and (5) structural. We assessed deaths
via phone calls and the South African National Population
Register. We used multivariable Cox proportional hazards models
to determine the association between number of perceived
barriers and death within 1 year.
Results: One thousand eight hundred ninety-nine HIV-infected
participants enrolled. Median age was 33 years (interquartile
range: 27–41 years), 49% were females, and median CD4 count
was 192/mL (interquartile range: 72–346/mL). One thousand
ﬁfty-seven participants (56%) reported no, 370 (20%) reported
1–3, and 460 (24%) reported .3 barriers to care. By 1 year, 250
[13%, 95% conﬁdence interval (CI): 12% to 15%] participants
died. Adjusting for age, sex, education, baseline CD4 count,
distance to clinic, and tuberculosis status, participants with 1–3
barriers (adjusted hazard ratio: 1.49, 95% CI: 1.06 to 2.08)
and .3 barriers (adjusted hazard ratio: 1.81, 95% CI: 1.35 to
2.43) had higher 1-year mortality risk compared with those
without barriers.
Conclusions: HIV-infected individuals in South Africa who
reported perceived barriers to medical care at diagnosis were more
likely to die within 1 year. Targeted structural interventions, such as
extended clinic hours, travel vouchers, and streamlined clinic
operations, may improve linkage to care and antiretroviral therapy
initiation for these people.
Key Words: mortality, barriers to care, HIV/TB coinfection, South
Africa
(J Acquir Immune Deﬁc Syndr 2017;74:432–438)
INTRODUCTION
People living with HIV (PLWH) in sub-Saharan Africa
who consistently receive antiretroviral therapy (ART) can
achieve a life expectancy similar to that of the general
population.1,2 South Africa is home to nearly 7 million
PLWH, leading to more than 180,000 deaths annually.3
Despite having the largest ART program in the world, 58%
of South Africans with HIV are not on treatment.4 Those
diagnosed with HIV but not yet on ART experience high
mortality rates, as do those initiated on ART but who are
inconsistently in care.4–9
We and others have documented high rates of loss to
follow-up and mortality after HIV or tuberculosis (TB)
diagnosis but before treatment initiation.5,10–17 Accurate
ascertainment of mortality, particularly among those classi-
ﬁed as lost to follow-up, is critical for evaluating the success
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of ART programs. Furthermore, studies evaluating risk of
mortality in sub-Saharan Africa have only minimal clinical
data assessing potential predictors of risk.8 However, contex-
tual factors, poor emotional health, lack of social support, and
competing needs at the time of diagnosis are likely to have an
important effect on linkage to care and survival.18,19
PLWH in sub-Saharan Africa cite barriers to care,
including low perceived need (because of not feeling sick
enough to require treatment), structural factors (eg, trans-
portation), and health system characteristics (eg, long wait
times for care), as reasons for delaying ART initiation.18,19 Our
objective was to evaluate whether self-identiﬁed barriers are
independent predictors of mortality among newly diagnosed
PLWH in Durban, South Africa. We hypothesized that these
issues are integrally related to each other and that reporting
self-perceived barriers to care at the time of HIV diagnosis
would be an independent predictor of 1-year mortality.
METHODS
Study Setting
This study includes participants from the Sizanani Trial
(NCT01188941), a randomized controlled trial that examined
the efﬁcacy of health system navigation and short messaging
service–based reminders to attend appointments and to
retrieve test results on linkage to and retention in HIV/TB
care. Because the randomized intervention did not lead to
a difference in linkage to HIV care, TB treatment completion,
or death between the 2 study arms, we analyzed both groups
together as a single cohort in the current study. The trial is
described in further detail elsewhere.20,21 Brieﬂy, participants
were enrolled between August 11, 2010, and January 16, 2013,
at 4 sites in the greater Durban area of South Africa: 2 out-
patient departments at McCord and St. Mary’s Hospitals and 2
primary health clinics. The McCord Hospital had a President’s
Emergency Plan for AIDS Relief (PEPFAR)–funded ART
clinic, Sinikithemba, which closed on June 15, 2012, because
of loss of PEPFAR funding; enrollment stopped at McCord’s
outpatient department on August 6, 2012.22 St. Mary’s Hos-
pital served a poorer peri-urban population 20 km west of
Durban; it similarly had a PEPFAR-funded ART clinic.
Participants were also enrolled at Tshelimnyama and Mariann-
hill, 2 nurse-driven municipal primary health clinics within the
service area of St. Mary’s Hospital. At the beginning of this
study, these municipal clinics offered HIV testing and referral
to St. Mary’s Hospital for ART initiation. As a part of South
Africa’s decentralization of HIV care, starting October 1, 2011,
these clinics began to offer ART and ongoing HIV care.
Participants
We enrolled English- or Zulu-speaking adults, 18 years
or older, voluntarily presenting for HIV testing and not
previously known to be living with HIV. We excluded
children and pregnant women from the study because they
entered HIV care through a separate system that had more
active linkage to care procedures. The current analysis
focuses on participants who were found to be HIV infected
at enrollment. The study was approved by the McCord
Hospital Medical Research Ethics Committee, St. Mary’s
Hospital Research Ethics Committee, University of KwaZulu-
Natal Biomedical Research Ethics Committee, and Partners
Institutional Review Board (Protocol 2011-P-001195,
Boston, MA).
A bilingual (Zulu/English) research assistant ap-
proached patients awaiting an HIV test to determine interest
in and eligibility for the study. Eligible willing participants
provided written informed consent in their preferred lan-
guage. Consent was followed by a 15- to 20-minute baseline
questionnaire to obtain detailed demographics and psychoso-
cial information regarding their emotional health, social
support, and self-perceived barriers to engaging in medical
care, after which HIV testing was completed.
Data Elements
Self-perceived Care Barriers
The questionnaire included 12 questions regarding
perceived barriers to care during the previous 6 months.23
We grouped these perceived care barriers into 5 categories
that included (1) concerns about service delivery (eg, waiting
too long to see a provider, not being treated with respect by
clinic staff), (2) ﬁnancial considerations (eg, inability to
afford medication or transport), (3) personal health perception
(eg, not being sick enough or being too sick), (4) logistical
(eg, failure to get out of work, having care responsibilities for
others), and (5) structural (eg, inability to access clinic
because of clinic hours or transport, not knowing where to
ﬁnd care).
Emotional Health and Social Support
To gauge emotional health, we asked questions adapted
from the 5-item Mental Health Inventory screening test and
calculated a mental health composite (MHC) score.24 The
questionnaire also contained 13 questions about availability
of social support. These questions incorporated 4 social
support scales (emotional/informational, tangible, positive
interaction, and affectionate) used to calculate the Social
Support Index (SSI) from the Medical Outcomes Study.25
The MHC and SSI scores were each averaged separately and
converted into 2 separate scales from 0 to 100, with higher
numbers corresponding to better emotional health and social
support. Based on the previous literature,26 we determined
that an MHC #52 indicated a positive depression screen and
we deﬁned an SSI below the study sample median to be a lack
of social support.27
At the end of the questionnaire, participants provided
their own contact information and that of a friend or family
member for tracking purposes.
Outcome Ascertainment
Nine months post-enrollment, study staff members con-
tacted the participants diagnosed with HIV at enrollment by
phone for a brief interview. They also collected HIV test dates
and results, CD4 counts, and the ﬁrst 3 ART dispensing dates
from electronic records and paper records at the study sites. We
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obtained vital status from clinical records, patients, and friends/
family members reached during follow-up phone calls. In
addition, we veriﬁed mortality data within 12 months of
enrollment using South African identiﬁcation numbers through
a crossmatch with the South African National Population
Register, which encompasses ;90% of all deaths nationwide.8
The primary endpoint was death. The observation time
was deﬁned as the time from study enrollment until 12
months following baseline study visit. Events were restricted
to the deaths that occurred within 12 months after the
participants’ baseline study interview. Study participants
who did not reach the primary endpoint by 12 months
were censored.
Analysis
We used descriptive statistics to characterize the study
sample. We built Cox proportional hazards models to
examine the association between number of self-perceived
barriers to care and time to death. Preliminary unadjusted
models were ﬁt independently for each independent variable
before adjusted models. Hazard ratios (HR) and 95%
conﬁdence intervals (CI) are reported for each model.
Preliminary analyses showed that each individual barrier
had similar impact on time to death [adjusted HR (aHR):
1.42–1.55]. Also, very few participants reported only a single
barrier or a combination of speciﬁc barriers. Given the results
of preliminary analyses, we built the ﬁnal model considering
a “number of self-perceived barriers to care” predictor
(0 barriers, 1–3 barriers, .3 barriers from the “Self-perceived
Care Barriers” listed above). The multivariable analysis
adjusted for age, sex, CD4 count category, education,
distance from clinic, and TB status at enrollment. Because
the randomized intervention did not lead to a difference in
linkage to HIV care, TB treatment completion, or death
between the 2 study arms, we analyzed both groups together
as a single cohort.21 We tested the proportional hazards
assumption on the ﬁnal adjusted model by creating a time-
dependent covariate. An interaction term between number of
self-perceived barriers to care and a function of survival time
was included in the model. The time-dependent covariate was
not signiﬁcant (P = 0.54) supporting the proportionality
assumption. We used an alpha of 0.05 to deﬁne the threshold
for statistical signiﬁcance. Analyses were performed using
SAS software (version 9.3; SAS Institute, Cary, NC).
Role of the Funding Source
The funding source had no impact on the design and
implementation of the study or data interpretation. The Data
Coordinating Center investigators (S.M.C. and C.E.C.) and
lead biostatistician (E.L.) had full data access.
RESULTS
Cohort Characteristics
Among 6536 people screened for the study, 4954
(76%) were eligible for enrollment and 4903 (99%) were
enrolled (Fig. 1). After enrollment, 1899 (39%) of the
participants were tested and newly diagnosed with HIV.
One thousand eight hundred eighty-seven (99%) of these
participants had complete baseline survey data and were
therefore included in this analysis. The median age was 33
years [interquartile range (IQR): 27–41 years], 928 (49%)
were females, and the median CD4 count was 192 cells/mL
(IQR: 72–346 cells/mL) with 848 (45%) presenting with
CD4 ,200 cells/mL (Table 1). Seven hundred seventy-four
(41%) of the participants had more than a high school
education, 1533 (81%) lived more than 5 km from a clinic,
253 (13%) reported at least one hospital stay in the previous
year, and 521 (28%) had positive TB testing on the day
of enrollment.
Mortality
By the end of the observation period, 250 (13%, 95%
CI: 12% to 15%) participants had died. Participants who
died were older (median age 37 years, IQR: 30–46 years)
compared with those alive at study conclusion (median age
33 years, IQR: 27–40 years, P , 0.0001) (Table 1). Those
who had baseline CD4 count ,200 cells/mL had a higher
risk of mortality than those with a baseline CD4 count .350
cells/mL (22% versus 3%, P , 0.0001). Risk of death was
greater among men than women (16% versus 10%, P =
0.0001), among those with less than a high school education
compared with those with at least some high school
education (16% versus 9%, P , 0.0001), among those
FIGURE 1. Participant flow. *Not mutually exclusive.
Bassett et al J Acquir Immune Defic Syndr  Volume 74, Number 4, April 1, 2017
434 | www.jaids.com Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc.
living more than 5 km from the enrollment site compared
with those living within 5 km of the site (14% versus 8%,
P = 0.0033), and among those who had a hospital stay in the
previous year compared with those who did not (27% versus
11%, P , 0.0001). Twenty percent of participants who had
TB at enrollment died compared with 11% of those who did
not have TB at enrollment (P , 0.0001). We did not ﬁnd
a statistically signiﬁcant or clinically relevant relationship
between emotional health or social support and mortality
(Table 2). Those who reported .3 self-perceived barriers to
care were twice as likely to die compared with those who
reported 3 or fewer barriers to care (22% versus 11%,
P , 0.0001).
Self-Reported Barriers to Care, Mental
Health, and Social Support at Enrollment
With respect to the 5 self-perceived care barrier catego-
ries, 566 (30%) reported service delivery barriers to care, 423
(22%) reported ﬁnancial barriers to care, 596 (32%) reported
personal health barriers to care, 334 (18%) reported logistical
barriers to care, and 540 (29%) reported structural barriers to
care (Table 2). Three hundred seventy participants (20%)
reported 1–3 self-perceived barriers to care and 460 (24%)
reported .3 barriers. Four hundred ﬁfty (24%) had a MHC
score #52, indicative of a positive depression screen, and
924 (49%) had a social support score less than the median
(Table 2).
TABLE 1. Cohort Characteristics of a Study of HIV Linkage to
Care and Mortality in Durban, South Africa
Overall,
n = 1887
Dead at
Study
Conclusion,
n = 250
Alive at
Study
Conclusion,
n = 1637 P
Age, yrs
Median (IQR) 33.0 (27–41) 37.0 (30–46) 33.0 (27–40) ,0.0001
Sex, n (%)
Male 959 (51) 155 (16) 804 (84) 0.0001
Female 928 (49) 95 (10) 833 (90)
CD4 count, cells/
mL, n (%)
0–199 848 (45) 187 (22) 661 (78) ,0.0001
200–350 400 (21) 24 (6) 376 (94)
.350 404 (21) 11 (3) 393 (97)
Education, n (%)
Some high
school or
greater
774 (41) 72 (9) 702 (91) ,0.0001
Primary school
or less
1112 (59) 178 (16) 934 (84)
Marital status,
n (%)
Never married 1537 (82) 188 (12) 1349 (88) 0.0240
Currently
married
265 (14) 47 (18) 218 (82)
Divorce/
separated/
widowed
85 (5) 15 (18) 70 (82)
Distance from
clinic, n (%)
Less than 5 km 354 (19) 30 (8) 324 (92) 0.0033
At least 5 km 1533 (81) 220 (14) 1313 (86)
Randomization
group, n (%)
Standard of care 927 (49) 119 (13) 808 (87) 0.6044
Intervention 960 (51) 131 (14) 829 (86)
Hospital stays,
n (%)
1 or more 253 (13) 68 (27) 185 (73) ,0.0001
None 1634 (87) 182 (11) 1452 (89)
Positive for TB at
enrollment,
n (%)
No 1366 (72) 146 (11) 1220 (89) ,0.0001
Yes 521 (28) 104 (20) 417 (80)
TABLE 2. Emotional Health, Social Support, and Perceived
Care Barriers at Baseline Among a Cohort of Newly Diagnosed
HIV-Infected Participants in Durban, South Africa
Overall,
n = 1887
Dead at Study
Conclusion,
n = 250
Alive at Study
Conclusion,
n = 1637 P
MHI #52, n (%)
No 1437 (76) 181 (13) 1256 (87) 0.1349
Yes 450 (24) 69 (15) 381 (85)
SSI ,Median
(67), n (%)
No 963 (51) 126 (13) 837 (87) 0.8297
Yes 924 (49) 124 (13) 800 (87)
Service delivery
barriers, n (%)
No 1321 (70) 139 (11) 1182 (89) ,0.0001
Yes 566 (30) 111 (20) 455 (80)
Financial
barriers, n (%)
No 1464 (78) 159 (11) 1305 (89) ,0.0001
Yes 423 (22) 91 (22) 332 (78)
Personal health
barriers, n (%)
No 1291 (68) 136 (11) 1155 (89) ,0.0001
Yes 596 (32) 114 (19) 482 (81)
Logistical
barriers, n (%)
No 1553 (82) 184 (12) 1369 (88) 0.0001
Yes 334 (18) 66 (20) 268 (80)
Structural
barriers, n (%)
No 1347 (71) 143 (11) 1204 (89) ,0.0001
Yes 540 (29) 107 (20) 433 (80)
No. perceived
barriers, n (%)
No barriers 1057 (56) 97 (9) 960 (91) ,0.0001
1–3 barriers 370 (20) 54 (15) 316 (85)
More than 3
barriers
460 (24) 99 (22) 361 (78)
MHI, Mental Health Inventory; SSI, Social Support Index.
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Predictors of Mortality: Results From
Multivariable Analyses
We found that participants who identiﬁed 1–3 self-
perceived barriers to care (aHR: 1.49, 95% CI: 1.06 to 2.08)
and.3 barriers (aHR: 1.81, 95% CI: 1.35 to 2.43) had higher
risk of 1-year mortality compared with those with no self-
identiﬁed barriers (Table 3).
DISCUSSION
Among 1887 PLWH enrolled in outpatient departments
in Durban, South Africa, 250 (13%) died within 1 year of
enrollment. Self-reported barriers to health care were common,
with 44% of the participants reporting at least one barrier to care
and 24% reporting more than 3 barriers to care. These self-
reported barriers were strong independent predictors of mortal-
ity, with a higher number of reported barriers correlating with
a greater risk of mortality. After adjusting for demographic
factors (ie, age, sex, and education) and clinical factors (ie, CD4
count and TB status at enrollment) known to be associated with
mortality in PLWH,28,29 participants who reported more than 3
barriers were nearly twice as likely to die within 1 year of
diagnosis compared with those who reported no barriers.
Screening for barriers is a distinctive and novel method for
identifying mortality risk when combined with additional
clinical tests, such as CD4 count and concomitant TB screening.
Personal health barriers, service delivery barriers, and
structural barriers were the most commonly perceived barriers
to care. Many patients presented to HIV testing with
incongruent perceptions of their health status, believing that
they were too well or not well enough to receive care. Our
results show that these incongruent perceptions can contribute
to an increased risk of mortality. Other research has revealed
that some patients, speciﬁcally those who feel healthy,
perceive that ART initiation is linked with side effects and
an overall decline in physical and mental health.30 As such,
adequate counseling at the time of HIV testing and after
diagnosis may improve linkage to care and ART initiation for
these patients; for example, psychological counseling and
adherence education were successful in improving TB
treatment adherence.31 Furthermore, participants who felt
that they were not treated with respect by clinic staff or that
they had to wait too long to receive care were also at
increased risk of death. Streamlined clinic operations and
improvements in staff training and workload may help
improve clinic operations and engagement in HIV care.32,33
Many participants found it difﬁcult to seek out care, as they
found clinic operating hours and transportation to be
inconvenient. Travel vouchers and extended clinic operating
hours could help link these patients to care.34,35 Although less
frequently reported, a substantial number of participants
reported ﬁnancial barriers and logistical barriers (eg, inability
to get days off from work or care responsibilities for others) to
care. Travel vouchers and extended clinic operating hours
may improve engagement in care for these participants.
A strength of our study was the ability to conﬁrm vital
status with the South African National Population Register.
This allowed a comprehensive assessment of mortality,
especially of those lost to follow-up during the study period.
In sub-Saharan Africa, a substantial proportion of patients
living with HIV are lost to follow-up during the process of
linking to care and after ART initiation.36,37 Furthermore,
patients who become lost to follow-up are at high risk of
mortality compared with patients who remain in care.38,39
Therefore, studies with signiﬁcant attrition in their patient
population may be underestimating mortality; using the South
African National Population Register, which accounts for
;90% of deaths nationally,8 can mitigate this issue.
A potential explanation of higher mortality in patients
who report barriers may be related to adherence to HIV care
(ie, ART and follow-up appointments). Previous studies have
established associations between suboptimal adherence and
perceived poor service delivery, a lack of ﬁnancial means for
transport, patient perception that he or she is feeling well,
responsibilities to care for dependents, and inconvenient
clinic hours.30,40–45 Suboptimal adherence to HIV care is
directly linked to poor virologic outcomes and mortality.46,47
Thus, it is possible that participants who reported barriers did
not adhere to HIV care, as a mechanism leading to increased
risk of death. Although we had previously found poor
emotional health to be associated with late presentation with
HIV and failure to obtain a CD4 count after diagnosis,27,48 we
TABLE 3. Socioeconomic Predictors of Mortality Among HIV- or TB-Infected Patients in Durban, South Africa
Unadjusted HR (95% CI) P aHR (95% CI) P
No. perceived barriers
No barriers 1.00 1.00
1–3 barriers 1.68 (1.20 to 2.34) 0.003 1.49 (1.06 to 2.08) 0.020
More than 3 barriers 2.54 (1.92 to 3.37) ,0.001 1.81 (1.35 to 2.43) ,0.001
Age at enrollment 1.02 (1.01 to 1.04) ,0.001
Male sex 1.34 (1.03 to 1.73) 0.030
CD4 count
.350 cells/mL 1.00
200–350 cells/mL 1.99 (0.97 to 4.11) 0.060
0–199 cells/mL 7.13 (3.85 to 13.19) ,0.001
,High school education 1.31 (0.98 to 1.76) 0.070
$5 km from clinic 1.37 (0.92 to 2.04) 0.130
TB at enrollment 1.21 (0.93 to 1.58) 0.160
Bassett et al J Acquir Immune Defic Syndr  Volume 74, Number 4, April 1, 2017
436 | www.jaids.com Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc.
did not ﬁnd an association between emotional health or social
support and mortality in the current study. Although social
support has been associated with reduced distress in PLWH,49
its impact on ART adherence has been mixed50–53; poor
emotional health has more frequently been associated with
nonadherence and accelerated disease progression, although
not uniformly.54–56 Because barriers were identiﬁed before
knowledge of HIV status, it is unclear how the new HIV
diagnosis itself would affect speciﬁc self-identiﬁed barriers or
whether the number of barriers is a proxy for another factor
associated with higher mortality.
These ﬁndings should be taken in light of several
limitations of the study. First, we did not have data related to
opportunistic infections (other than TB) or noninfectious
comorbidities that could be associated with mortality. It is
possible that a higher prevalence of these comorbidities could
have been present in participants who reported barriers to care.
Second, we were unable to determine the cause of death for
participants. Therefore, characterizing all these deaths as HIV
related may lead to an overestimate of HIV-related death.
However, regardless of the cause of death, it is likely that the
barriers characterized in this study are barriers to obtaining any
health care. As such, receiving clinical care and/or health
monitoring would likely be beneﬁcial in reducing mortality.
Third, women comprised 49% of the cohort, less than in
typical South African HIV cohorts. This may reﬂect that
pregnant women were excluded from the study and that we
enrolled participants before HIV testing. Fourth, we were
unable to determine the proportion of those “in care” before
death. Because outcomes were ascertained at study sites only,
the proportion on ART in the parent study may have been an
underestimate if participants sought care elsewhere. Finally, the
instruments used to predict mortality in this study may not be
readily transferable to routine clinical care. An important next
step in this work will be to develop a short clinically practical
screening instrument that can be used to stratify risk before
HIV testing, as has been done with alcoholism (CAGE) and
depression (PHQ-9, HADS, WBI-5, WHO-5, etc.).57–59
In conclusion, we found that newly diagnosed HIV
patients’ perceived barriers to care predict mortality risk
within 1 year. Those reporting multiple perceived barriers
to medical care at the time of diagnosis are nearly twice as
likely to die within 1 year compared with those without
barriers. Screening for barriers to care at HIV diagnosis can
help identify patients for targeted interventions that may
help link them to care and ART initiation, subsequently
reducing their likelihood of death. Targeted structural
interventions, such as extended clinic hours, travel vouch-
ers, and more streamlined clinic operations, may improve
outcomes for high-risk patients. The high prevalence of
patients who report multiple barriers to care underlines the
urgency for developing interventions that will alleviate
these barriers and attenuate mortality.
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